Fabrazyme is an approved treatment for Fabry disease patients age 8 and older. It was developed by Sanofi Genzyme. Following are answers to some frequently asked questions about the ... Read more
Fabry disease is a rare genetic disease characterized by the buildup of a fatty molecule — globotriaosylceramide Gb3 or GL-3 — inside cells, interfering with their function. The accumulation of ... Read more
Fabry disease is a rare disease characterized by the buildup of a fatty molecule (globotriaosylceramide Gb3 or GL-3) inside cells. This accumulation can lead to complications that include kidney disease. ... Read more
Patients and caregivers of genetic disorders such as Fabry disease often have more questions than answers due to the paucity of easily accessible information. This article answers some frequently ... Read more
